New gene-silencing drug aims to lower bad cholesterol without permanent DNA changes
NCT ID NCT07428473
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests STX-1150, a new medicine that temporarily turns off a gene (PCSK9) in the liver to lower bad cholesterol (LDL-C). It does not change your DNA. Up to 64 adults with high LDL-C will receive one or more doses and be followed for a year. The main goal is to check safety and how well the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ELEVATED LDL-C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Monash Health/ Victorian Heart Hospital (VHH)
Clayton, Victoria, 3168, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••